Hyperfine, Inc.

HYPR
About the company

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system.

Country: United StatesPrice: $0.63Market Cap: $66.7M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

2 / 12

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

7 of 12 pass — Buffett, Lynch, Akre +2 more object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2964 (Top 95.7%)PASSFAILFAILFAILFAILFAILPASSNEUTRALFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-18

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-18

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-18

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-18

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-18

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage58% pass✓ 10✗ 5▾

    7 of 12 pass — Buffett, Lynch, Akre +2 more object

    Debt Levels0.42
    ✓MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    LT Debt vs Net Current AssetsLT Debt $13.4M vs NCA $43.2M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest Coverage
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.42
    ✗Lynch< 0.33
    Cash - Long-term Debt$24.5M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities5.10
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.42
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Interest Coverage & Debt/EBITDA
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.42
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.4206; #2294/4210 (top 54.5%)
    ✗AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✓ 4✗ 24▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / Book Value per Share1.3x
    ✗Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio1.3x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-75.7%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-75.7%, ROC=-429.5%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Valuation Reasonableness
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-43.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=1.3x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low104% of trailing low ($0.60)
    ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-44.67%; #4999/6340 (top 78.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.4757; #2974/6449 (top 46.1%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share1.25x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.2856; #3388/5247 (top 64.6%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-41.84%; #3794/4519 (top 84.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-62.11%; #5451/6202 (top 87.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✓ 1✗ 11▾

    No clean pass — all 10 investors flag at least one cash flow criterion

    Free Cash Flow Proxy$-43.8M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-27.9M
    ✗LynchPositive and growing
    Operating Cash Flow$-27.9M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-50.57%, ROA=-64.37%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-43.7%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/6 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-54.3%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency0/6 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-27.9M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-41.84%; #3794/4519 (top 84.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Profitability6% pass✓ 6✗ 29▾

    15 of 16 flag HYPR's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)0/7 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)0/7 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-58.6%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-273.4% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-43.8M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-93.9%
    ✗Lynch> 15%
    EBIT / Enterprise Value-75.7%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-75.7%, ROC=-429.5%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-64.37%
    ✗PiotroskiROA > 0
    ROA Change YoY-69.13% -> -64.37% (delta: +4.76%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-50.57%, ROA=-64.37%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY45.7% -> 49.8%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue-156.4%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-93.9%
    ✗Dreman> 12%
    Margin of SafetyP/B=1.3x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-74.1% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency0/6 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-167.6%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-93.9%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-436.1% (2023) -> -273.4% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 43.1% -> 49.8%, operating margin -436.1% -> -273.4%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-44.67%; #4999/6340 (top 78.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+17.36%; #2246/3702 (top 60.7%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity-93.92%; #4565/5226 (top 87.4%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.1543; #3963/5884 (top 67.4%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years0/6 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Growth13% pass✓ 4✗ 9▾

    7 of 8 flag HYPR's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 9.2% vs Rev: 80.0%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$-15.38 (2020) -> $-0.43 (2025)
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency0/6 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth16.8%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency4/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 43.1% -> 49.8%, operating margin -436.1% -> -273.4%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR115.2%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Verdicts13% pass✓ 2✗ 13▾

    Split decision: 12 FAIL · 2 PASS · 2 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (3/9)✗BuffettFAIL (1/9)✗LynchFAIL (2/7)✗GreenblattRank #2964✓PiotroskiPASS (F-Score 5)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✓AckmanPASS (4/9)•TempletonNEUTRAL (5/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #2149/2370 (Top 90.7%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag HYPR's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio5.10
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)
    ✗Buffett> 10%
    ROIC - WACC
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-429.5%
    ✗Greenblatt> 25%
    Current Ratio Change YoY6.15 -> 4.34
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.22x -> 0.25x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities5.10
    ✓Dreman> 1.5
    Return on Invested Capital-56.0%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Medical Equipment
SIC Sector: Measuring & Medical Instruments
Size: Micro Cap($66.7M)
Revenue: $13.6M+5.2% YoY
Net Income: $35.6M+12.6% YoY

Financial Snapshot

Operating Margin-273.4%
Return on Equity-86.8%
Debt / Equity--
Current Ratio4.34
EPS (Diluted)$-0.43
Shares Retired−13.0% / −14.7% 2y

Similar Companies

ALCALCON INC
$35.6B
PHGKONINKLIJKE PHILIPS NV
$29.7B
WSTWEST PHARMACEUTICAL SERVICES INC
$29.0B
SNNSMITH & NEPHEW PLC
$13.1B

Shareholder Return

Fiscal 2025

Issued 13.0% of shares last year, 14.7% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-03-18
FY 2024
Sources
  • 10-K · 2025-03-17
FY 2023
Sources
  • 10-K · 2024-03-22
FY 2022
Sources
  • 10-K · 2023-03-22
FY 2021
Sources
  • 10-K · 2022-03-25
Market Cap$66.7Mcurrent------$91.6Mest.$79.7Mest.$76.3Mest.$67.8Mest.$16.2Mest.
Revenue$19.1M↑80%$6.0M↑73%$3.9M↑45%$3.9M↑83%$13.6M↑5%$12.9M↑17%$11.0M↑62%$6.8M↑355%$1.5M
Operating Income-$32.0M↑20%-$7.3M↑19%-$8.5M↑12%-$8.6M↑22%-$37.1M↑14%-$43.2M↑10%-$48.1M↑35%-$73.9M↓14%-$64.9M
Net Income-$29.8M↑26%-$6.0M↑46%-$9.3M↓1%-$8.6M↑8%-$35.6M↑13%-$40.7M↑8%-$44.2M-$44.2M↑32%-$64.9M
EPS (Diluted)--$-0.06↑57%$-0.09↑25%$-0.09↑25%$-0.43↑23%$-0.56↑10%$-0.62↑40%$-1.04↑94%$-17.57
Gross Margin52.6%↑14%56.7%↑6%50.7%↑3%50.7%↑23%49.8%↑9%45.7%↑6%43.1%↑224%13.3%↑117%-78.0%
Operating Margin-167.6%↑56%-121.8%↑53%-216.9%↑39%-219.3%↑57%-273.4%↑18%-335.3%↑23%-436.1%↑60%-1084.2%↑75%-4336.1%
ROE-93.9%↑37%———-86.8%↓4%-83.0%↓58%-52.4%↓47%-35.8%↓3%-34.8%
Total Debt$13.4M$13.4M$13.2M$13.1M----------
Shareholders' Equity$31.7M↑18%$31.7M↑18%$36.8M↑5%$34.4M↓20%$41.0M↓16%$49.0M↓42%$84.4M↓32%$123.7M↓34%$186.2M
Current Ratio5.10↑41%5.10↑41%6.15↑23%5.52↓9%4.34↓29%6.15↓39%10.14↓31%14.62↑16%12.55
Debt / Equity0.420.420.360.38—————
Operating Cash Flow-$27.6M↑11%-$6.1M↓9%-$7.3M↑8%-$9.0M↑3%-$27.9M↑28%-$38.8M↑7%-$41.8M↑42%-$72.3M↓53%-$47.2M
Free Cash Flow-$27.9M↑13%-$6.1M↓7%-$7.3M↑13%-$9.3M↑5%-$29.1M↑26%-$39.1M↑8%-$42.6M↑42%-$72.9M↓46%-$49.9M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Medical Equipment

HYPR vs Peers — Financial Grading

Revenue$13.6MBottom 25%
Net Income$35.6MBottom 25%
ROE-86.8%Bottom 25%
D/E—
Op. Margin-273.4%Bottom 25%
Curr. Ratio4.34Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11